 | • レポートコード：QFJ1-6064 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、VEGF阻害薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（チロシンキナーゼ阻害剤、モノクローナル抗体、その他）、用途別市場規模（腫瘍内科、眼科、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・VEGF阻害薬の市場動向 ・企業の競争状況、市場シェア ・VEGF阻害薬の種類別市場規模と予測2016-2027（チロシンキナーゼ阻害剤、モノクローナル抗体、その他） ・VEGF阻害薬の用途別市場規模と予測2016-2027（腫瘍内科、眼科、その他） ・VEGF阻害薬の北米市場規模2016-2027（アメリカ、カナダ） ・VEGF阻害薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・VEGF阻害薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・VEGF阻害薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・VEGF阻害薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Novartis AG、GlaxoSmithKline plc、Sanofi、AstraZeneca plc、Bristol-Myers-Squibb Company、Genentech, Inc. (Roche)、Merck & Co., Inc.、Bayer AG、Eli Lilly & Company） ・結論 |
Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells.
Market Analysis and Insights: Global VEGF Inhibitor Drugs Market
The global VEGF Inhibitor Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global VEGF Inhibitor Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global VEGF Inhibitor Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global VEGF Inhibitor Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global VEGF Inhibitor Drugs market.
Global VEGF Inhibitor Drugs Scope and Market Size
VEGF Inhibitor Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global VEGF Inhibitor Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Novartis AG
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Bristol-Myers-Squibb Company
Genentech, Inc. (Roche)
Merck & Co., Inc.
Bayer AG
Eli Lilly & Company
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Market by Application
1.3.1 Global VEGF Inhibitor Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global VEGF Inhibitor Drugs Market Perspective (2016-2027)
2.2 VEGF Inhibitor Drugs Growth Trends by Regions
2.2.1 VEGF Inhibitor Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 VEGF Inhibitor Drugs Historic Market Share by Regions (2016-2021)
2.2.3 VEGF Inhibitor Drugs Forecasted Market Size by Regions (2022-2027)
2.3 VEGF Inhibitor Drugs Industry Dynamic
2.3.1 VEGF Inhibitor Drugs Market Trends
2.3.2 VEGF Inhibitor Drugs Market Drivers
2.3.3 VEGF Inhibitor Drugs Market Challenges
2.3.4 VEGF Inhibitor Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top VEGF Inhibitor Drugs Players by Revenue
3.1.1 Global Top VEGF Inhibitor Drugs Players by Revenue (2016-2021)
3.1.2 Global VEGF Inhibitor Drugs Revenue Market Share by Players (2016-2021)
3.2 Global VEGF Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by VEGF Inhibitor Drugs Revenue
3.4 Global VEGF Inhibitor Drugs Market Concentration Ratio
3.4.1 Global VEGF Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by VEGF Inhibitor Drugs Revenue in 2020
3.5 VEGF Inhibitor Drugs Key Players Head office and Area Served
3.6 Key Players VEGF Inhibitor Drugs Product Solution and Service
3.7 Date of Enter into VEGF Inhibitor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 VEGF Inhibitor Drugs Breakdown Data by Type
4.1 Global VEGF Inhibitor Drugs Historic Market Size by Type (2016-2021)
4.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2022-2027)
5 VEGF Inhibitor Drugs Breakdown Data by Application
5.1 Global VEGF Inhibitor Drugs Historic Market Size by Application (2016-2021)
5.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America VEGF Inhibitor Drugs Market Size (2016-2027)
6.2 North America VEGF Inhibitor Drugs Market Size by Type
6.2.1 North America VEGF Inhibitor Drugs Market Size by Type (2016-2021)
6.2.2 North America VEGF Inhibitor Drugs Market Size by Type (2022-2027)
6.2.3 North America VEGF Inhibitor Drugs Market Size by Type (2016-2027)
6.3 North America VEGF Inhibitor Drugs Market Size by Application
6.3.1 North America VEGF Inhibitor Drugs Market Size by Application (2016-2021)
6.3.2 North America VEGF Inhibitor Drugs Market Size by Application (2022-2027)
6.3.3 North America VEGF Inhibitor Drugs Market Size by Application (2016-2027)
6.4 North America VEGF Inhibitor Drugs Market Size by Country
6.4.1 North America VEGF Inhibitor Drugs Market Size by Country (2016-2021)
6.4.2 North America VEGF Inhibitor Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe VEGF Inhibitor Drugs Market Size (2016-2027)
7.2 Europe VEGF Inhibitor Drugs Market Size by Type
7.2.1 Europe VEGF Inhibitor Drugs Market Size by Type (2016-2021)
7.2.2 Europe VEGF Inhibitor Drugs Market Size by Type (2022-2027)
7.2.3 Europe VEGF Inhibitor Drugs Market Size by Type (2016-2027)
7.3 Europe VEGF Inhibitor Drugs Market Size by Application
7.3.1 Europe VEGF Inhibitor Drugs Market Size by Application (2016-2021)
7.3.2 Europe VEGF Inhibitor Drugs Market Size by Application (2022-2027)
7.3.3 Europe VEGF Inhibitor Drugs Market Size by Application (2016-2027)
7.4 Europe VEGF Inhibitor Drugs Market Size by Country
7.4.1 Europe VEGF Inhibitor Drugs Market Size by Country (2016-2021)
7.4.2 Europe VEGF Inhibitor Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific VEGF Inhibitor Drugs Market Size (2016-2027)
8.2 Asia-Pacific VEGF Inhibitor Drugs Market Size by Type
8.2.1 Asia-Pacific VEGF Inhibitor Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific VEGF Inhibitor Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific VEGF Inhibitor Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific VEGF Inhibitor Drugs Market Size by Application
8.3.1 Asia-Pacific VEGF Inhibitor Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific VEGF Inhibitor Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific VEGF Inhibitor Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region
8.4.1 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America VEGF Inhibitor Drugs Market Size (2016-2027)
9.2 Latin America VEGF Inhibitor Drugs Market Size by Type
9.2.1 Latin America VEGF Inhibitor Drugs Market Size by Type (2016-2021)
9.2.2 Latin America VEGF Inhibitor Drugs Market Size by Type (2022-2027)
9.2.3 Latin America VEGF Inhibitor Drugs Market Size by Type (2016-2027)
9.3 Latin America VEGF Inhibitor Drugs Market Size by Application
9.3.1 Latin America VEGF Inhibitor Drugs Market Size by Application (2016-2021)
9.3.2 Latin America VEGF Inhibitor Drugs Market Size by Application (2022-2027)
9.3.3 Latin America VEGF Inhibitor Drugs Market Size by Application (2016-2027)
9.4 Latin America VEGF Inhibitor Drugs Market Size by Country
9.4.1 Latin America VEGF Inhibitor Drugs Market Size by Country (2016-2021)
9.4.2 Latin America VEGF Inhibitor Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa VEGF Inhibitor Drugs Market Size (2016-2027)
10.2 Middle East & Africa VEGF Inhibitor Drugs Market Size by Type
10.2.1 Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa VEGF Inhibitor Drugs Market Size by Application
10.3.1 Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country
10.4.1 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer VEGF Inhibitor Drugs Introduction
11.1.4 Pfizer Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG VEGF Inhibitor Drugs Introduction
11.2.4 Novartis AG Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.2.5 Novartis AG Recent Development
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Company Details
11.3.2 GlaxoSmithKline plc Business Overview
11.3.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Introduction
11.3.4 GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.3.5 GlaxoSmithKline plc Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi VEGF Inhibitor Drugs Introduction
11.4.4 Sanofi Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.4.5 Sanofi Recent Development
11.5 AstraZeneca plc
11.5.1 AstraZeneca plc Company Details
11.5.2 AstraZeneca plc Business Overview
11.5.3 AstraZeneca plc VEGF Inhibitor Drugs Introduction
11.5.4 AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.5.5 AstraZeneca plc Recent Development
11.6 Bristol-Myers-Squibb Company
11.6.1 Bristol-Myers-Squibb Company Company Details
11.6.2 Bristol-Myers-Squibb Company Business Overview
11.6.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Introduction
11.6.4 Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.6.5 Bristol-Myers-Squibb Company Recent Development
11.7 Genentech, Inc. (Roche)
11.7.1 Genentech, Inc. (Roche) Company Details
11.7.2 Genentech, Inc. (Roche) Business Overview
11.7.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Introduction
11.7.4 Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.7.5 Genentech, Inc. (Roche) Recent Development
11.8 Merck & Co., Inc.
11.8.1 Merck & Co., Inc. Company Details
11.8.2 Merck & Co., Inc. Business Overview
11.8.3 Merck & Co., Inc. VEGF Inhibitor Drugs Introduction
11.8.4 Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.8.5 Merck & Co., Inc. Recent Development
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG VEGF Inhibitor Drugs Introduction
11.9.4 Bayer AG Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.9.5 Bayer AG Recent Development
11.10 Eli Lilly & Company
11.10.1 Eli Lilly & Company Company Details
11.10.2 Eli Lilly & Company Business Overview
11.10.3 Eli Lilly & Company VEGF Inhibitor Drugs Introduction
11.10.4 Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2016-2021)
11.10.5 Eli Lilly & Company Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tyrosine Kinase Inhibitors
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Others
Table 5. Global VEGF Inhibitor Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global VEGF Inhibitor Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global VEGF Inhibitor Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global VEGF Inhibitor Drugs Market Share by Regions (2016-2021)
Table 9. Global VEGF Inhibitor Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global VEGF Inhibitor Drugs Market Share by Regions (2022-2027)
Table 11. VEGF Inhibitor Drugs Market Trends
Table 12. VEGF Inhibitor Drugs Market Drivers
Table 13. VEGF Inhibitor Drugs Market Challenges
Table 14. VEGF Inhibitor Drugs Market Restraints
Table 15. Global VEGF Inhibitor Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global VEGF Inhibitor Drugs Market Share by Players (2016-2021)
Table 17. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VEGF Inhibitor Drugs as of 2020)
Table 18. Ranking of Global Top VEGF Inhibitor Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by VEGF Inhibitor Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players VEGF Inhibitor Drugs Product Solution and Service
Table 22. Date of Enter into VEGF Inhibitor Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global VEGF Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global VEGF Inhibitor Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America VEGF Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America VEGF Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America VEGF Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America VEGF Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America VEGF Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America VEGF Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe VEGF Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe VEGF Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe VEGF Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe VEGF Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe VEGF Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe VEGF Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific VEGF Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific VEGF Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific VEGF Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific VEGF Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America VEGF Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America VEGF Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America VEGF Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America VEGF Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America VEGF Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America VEGF Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa VEGF Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa VEGF Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer VEGF Inhibitor Drugs Product
Table 65. Pfizer Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Novartis AG Company Details
Table 68. Novartis AG Business Overview
Table 69. Novartis AG VEGF Inhibitor Drugs Product
Table 70. Novartis AG Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 71. Novartis AG Recent Development
Table 72. GlaxoSmithKline plc Company Details
Table 73. GlaxoSmithKline plc Business Overview
Table 74. GlaxoSmithKline plc VEGF Inhibitor Drugs Product
Table 75. GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 76. GlaxoSmithKline plc Recent Development
Table 77. Sanofi Company Details
Table 78. Sanofi Business Overview
Table 79. Sanofi VEGF Inhibitor Drugs Product
Table 80. Sanofi Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. AstraZeneca plc Company Details
Table 83. AstraZeneca plc Business Overview
Table 84. AstraZeneca plc VEGF Inhibitor Drugs Product
Table 85. AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 86. AstraZeneca plc Recent Development
Table 87. Bristol-Myers-Squibb Company Company Details
Table 88. Bristol-Myers-Squibb Company Business Overview
Table 89. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product
Table 90. Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 91. Bristol-Myers-Squibb Company Recent Development
Table 92. Genentech, Inc. (Roche) Company Details
Table 93. Genentech, Inc. (Roche) Business Overview
Table 94. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product
Table 95. Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 96. Genentech, Inc. (Roche) Recent Development
Table 97. Merck & Co., Inc. Company Details
Table 98. Merck & Co., Inc. Business Overview
Table 99. Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 100. Merck & Co., Inc. Recent Development
Table 101. Bayer AG Company Details
Table 102. Bayer AG Business Overview
Table 103. Bayer AG VEGF Inhibitor Drugs Product
Table 104. Bayer AG Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 105. Bayer AG Recent Development
Table 106. Eli Lilly & Company Company Details
Table 107. Eli Lilly & Company Business Overview
Table 108. Eli Lilly & Company VEGF Inhibitor Drugs Product
Table 109. Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 110. Eli Lilly & Company Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global VEGF Inhibitor Drugs Market Share by Type: 2020 VS 2027
Figure 2. Tyrosine Kinase Inhibitors Features
Figure 3. Monoclonal Antibodies Features
Figure 4. Others Features
Figure 5. Global VEGF Inhibitor Drugs Market Share by Application: 2020 VS 2027
Figure 6. Oncology Case Studies
Figure 7. Ophthalmology Case Studies
Figure 8. Others Case Studies
Figure 9. VEGF Inhibitor Drugs Report Years Considered
Figure 10. Global VEGF Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global VEGF Inhibitor Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global VEGF Inhibitor Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global VEGF Inhibitor Drugs Market Share by Regions (2022-2027)
Figure 14. Global VEGF Inhibitor Drugs Market Share by Players in 2020
Figure 15. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VEGF Inhibitor Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by VEGF Inhibitor Drugs Revenue in 2020
Figure 17. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America VEGF Inhibitor Drugs Market Share by Type (2016-2027)
Figure 21. North America VEGF Inhibitor Drugs Market Share by Application (2016-2027)
Figure 22. North America VEGF Inhibitor Drugs Market Share by Country (2016-2027)
Figure 23. United States VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe VEGF Inhibitor Drugs Market Share by Type (2016-2027)
Figure 27. Europe VEGF Inhibitor Drugs Market Share by Application (2016-2027)
Figure 28. Europe VEGF Inhibitor Drugs Market Share by Country (2016-2027)
Figure 29. Germany VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific VEGF Inhibitor Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific VEGF Inhibitor Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific VEGF Inhibitor Drugs Market Share by Region (2016-2027)
Figure 39. China VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America VEGF Inhibitor Drugs Market Share by Type (2016-2027)
Figure 47. Latin America VEGF Inhibitor Drugs Market Share by Application (2016-2027)
Figure 48. Latin America VEGF Inhibitor Drugs Market Share by Country (2016-2027)
Figure 49. Mexico VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa VEGF Inhibitor Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa VEGF Inhibitor Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa VEGF Inhibitor Drugs Market Share by Country (2016-2027)
Figure 55. Turkey VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE VEGF Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Pfizer Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 59. Novartis AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 60. GlaxoSmithKline plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 61. Sanofi Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 62. AstraZeneca plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 63. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 64. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 65. Merck & Co., Inc. Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 66. Bayer AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 67. Eli Lilly & Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
世界の血管内皮増殖因子（VEGF）阻害剤市場規模・現状・予測（2021年-2027年） Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels. The vascular endothelial growth factor is a protein that can trigger endothelial cells or pre-existing vessels to form new blood vessels. However, overexpression of …- 血管内皮増殖因子(VEGF)阻害剤のグローバル市場：規模・現状・予測2019-2025 Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels. The vascular endothelial growth factor is a protein that can trigger endothelial cells or pre-existing vessels to form new blood vessels. However, overexpression of …
- 血管内皮増殖因子(VEGF)阻害剤のグローバル市場：規模・現状・予測2019-2025 Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels. The vascular endothelial growth factor is a protein that can trigger endothelial cells or pre-existing vessels to form new blood vessels. However, overexpression of …
- 世界の腫瘍壊死因子（TNF）阻害薬市場規模・現状・予測（2021年-2027年） A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, …
- 腫瘍壊死因子(TNF)阻害薬のグローバル市場：規模・現状・予測2019-2025 A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, …